Singapore, Jan 6, 2009:  Regenerative medicine company Mesoblast Limited announced that it has received the 2009 Frost & Sullivan Emerging Company Award in the United States Soft Tissue Repair market.

 

The Frost & Sullivan Award for Emerging Company is presented each year to the company that has emerged as a significant participant within its industry. The Award citation states that Mesoblast has “immense potential to be a significant contributor and promoter of the orthopedic soft tissue and cartilage repair space, and to establish a strong presence in the United States orthopedic market.”

 

According to Frost & Sullivan, Mesoblast is perceived to have exhibited outstanding management, superior market growth, exceptional customer service, and the ability to combine technology and successful strategic initiatives. The Award recognizes Mesoblast’s exceptional know-how to take advantage of market changes through the execution of innovative strategies within the existing competitive landscape. The selection of this award is based on interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.

 

“Mesoblast has made its own niche using first-of-a-kind adult stem cell technology. The company’s strength lies in the uniqueness of its offering, which is a markedly different approach from other manufacturers in the market. Mesoblast has the ability to explore and meet the demands of newer areas in the soft tissue repair market, which will lead to higher revenues and increased market share,” noted Ms Aarti Shetty, industry analyst, Frost & Sullivan.

Prof Silviu Itescu, Executive Director, Mesoblast said, “Receiving the prestigious Frost & Sullivan Emerging Company Award reinforces Mesoblast’s leadership position within the rapidly growing biologics market in orthopedics. We will continue to focus on timely commercialization of our novel therapies for prevalent disorders of bone, cartilage, and soft tissue which represent major unmet clinical needs."